… The two front-running candidate vaccines are one using the ChAdOx1 platform, being developed by the University of Oxford and the Serum Institute of India, and another being worked on by US pharma firm Moderna using mRNA technology. …
… The first is the PARTNERS trial, coordinated by the World Health Organization (WHO) in collaboration with the DRC's National Institute for Biomedical Research (INRB), the Institute of Tropical Medicine Antwerp, the University of Oxford and Africa CDC. …
… Researchers at the University of Oxford produced the vaccine candidate just 57 days after the World Health Organisation declared the outbreak a Public Health Emergency of International Concern, with hopes it could provide long-term protection if proven safe and effective.Meanwhil …
… The current trial is sponsored by the WHO, and is being co-ordinated by scientists at the Institut National de Recherche Biomédicale in DRC, the Institute of Tropical Medicine in Belgium, and the University of Oxford in the UK. …
… The trial is sponsored by the World Health Organization (WHO) and coordinated by the Institut National pour la Recherche Biomédicale (INRB) in the DRC, the Institute of Tropical Medicine in Belgium, and the University of Oxford in the United Kingdom, in collaboration with interna …
… The cost was "too high," said Mahmood. - 'Extra tax' - Madeleine Sumption, director of the Migration Observatory at the University of Oxford, said it was unlikely many refugees would earn enough to be able to refund any costs. …
… The trials are being coordinated with partners in the Democratic Republic of Congo, Uganda, and international research institutions, including the University of Oxford. …
The World Health Organization called for more financial and other resources to combat the Ebola outbreak in the Democratic Republic of Congo, which it described as the biggest ever to have hit the DRC and is still expanding beyond the capacity of response efforts. There have been 3,802 confirmed cases with 1,707 deaths, according to WHO figures.
The World Health Organization called for more financial and other resources to combat the Ebola outbreak in the Democratic Republic of Congo, which it described as the biggest ever to have hit the DRC and is still expanding beyond the capacity of response efforts. There have been 3,802 confirmed cases with 1,707 deaths, according to WHO figures.
The WHO warned Thursday that Ebola was spreading in the Democratic Republic of Congo more quickly than during any previous outbreak. More than 2,000 cases including 796 deaths have been confirmed since the outbreak was declared two months ago, making it the third-largest Ebola outbreak on record.
The World Health Organization warned that Ebola was spreading in the Democratic Republic of Congo more quickly than during any previous outbreak. More than 2,000 confirmed cases including 796 deaths have been reported since the outbreak was declared two months ago, compared to the 2018-2020 outbreak which took more than 10 months to reach 2,000 cases.
The US Centers for Disease Control and Prevention and Department of Homeland Security have maintained stringent travel measures, including a Do Not Board list, for people departing the Democratic Republic of the Congo to prevent Bundibugyo Ebola importation during the country's largest recorded outbreak. An American physician infected with the virus while working in the DRC is receiving treatment in Germany.
Scientists have launched EBO-PEP, the first clinical trial evaluating post-exposure prophylaxis with an experimental antiviral pill called obeldesivir for Bundibugyo Ebola, among high-risk contacts including family members and healthcare workers in the Democratic Republic of Congo and Uganda. If successful, it would become the first proven strategy to prevent Bundibugyo Ebola after exposure.
The WHO has announced the start of a trial testing potential treatments for the Bundibugyo virus strain of Ebola in the Democratic Republic of Congo, with the first patient already enrolled. More than 1,400 cases and 438 deaths have been confirmed in the DRC, and the trial is being coordinated by scientists across institutions in DRC, Belgium, and the UK.
An international trial in the Democratic Republic of the Congo has begun enrolling patients to evaluate whether a monoclonal antibody called MBP134 and the antiviral drug remdesivir can improve survival for Bundibugyo virus disease, a rare strain of Ebola for which no approved treatment currently exists.
The British government introduced new rules on Tuesday requiring asylum seekers granted refuge in the UK to pay Ksh.1.6 million towards their accommodation if they earn enough, as part of efforts to curb irregular immigration.
The United States has provided doses of an experimental antibody drug developed by Mapp Biopharmaceutical to support clinical trials in the Democratic Republic of Congo's Ebola outbreak, marking a shift from prior US-only availability. The move comes as health authorities work to contain a rapidly spreading Bundibugyo strain outbreak that has recorded more than 1,000 cases and over 250 deaths.
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for clinical trials in the Democratic Republic of Congo's Bundibugyo Ebola outbreak, which has caused over 1,000 cases and more than 250 deaths. The trial data could inform future U.S. regulatory review and potential approval.
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials and compassionate use to fight an Ebola outbreak in Democratic Republic of Congo. The Bundibugyo strain has caused more than 1,000 cases in Congo and more than 250 deaths, with a handful of cases also reported in Uganda.
More than 875 cases of the Bundibugyo Ebola strain have been confirmed, including 202 deaths, in a little over a month across DR Congo and Uganda, with no currently available vaccines or treatments for this strain. Scientists and pharmaceutical companies are racing to develop new vaccines and treatments, with the WHO calling an rVSV-based vaccine candidate "most promising" and estimating it will take seven to nine months before human testing can begin.
A Reuters Institute report based on surveys of almost 100,000 people across 48 countries found that 54 percent of respondents got news from social media or video platforms in the week before the survey, exceeding the 52 percent who referenced TV news. This marks the first year social media and video network consumption is ahead of other news sources globally.
The Serum Institute of India is leading development of a vaccine targeting the Bundibugyo strain of Ebola in response to an outbreak in the Democratic Republic of Congo first reported in May 2026, which the WHO has declared a Public Health Emergency of International Concern. The vaccine, developed with the University of Oxford and CEPI, uses the same viral vector technology as the Oxford-AstraZeneca COVID-19 vaccine and trial doses are expected in the coming months.
Non-profit organisations announced Monday they are ramping up efforts to develop a vaccine for the Bundibugyo strain of Ebola, which has caused an outbreak in the Democratic Republic of Congo and Uganda with nearly 250 suspected deaths and more than 1,100 infections. The strain, for which there are no approved vaccines or treatments, has prompted a race to rapidly develop, manufacture and test a vaccine in clinical trials in the affected region.
The 2001 Nobel Prize in Literature award to V.S. Naipaul prompted backlash from the literary community, including Nobel laureate Wole Soyinka, who objected to what they saw as the committee endorsing Naipaul's contemptuous attitude toward his country of origin, Trinidad and Tobago. Naipaul's work portrays broken societies and fractured systems, including depictions of education as uncertain and arbitrary.
Monica Juma of Kenya has assumed office in Vienna as Director-General of the UN Office at Vienna and Executive Director of the UN Office on Drugs and Crime (UNODC), following her appointment by UN Secretary-General António Guterres. She previously served as Kenya's first National Security Adviser and held Cabinet Secretary positions in Energy, Defence, and other strategic ministries.
Kenyan diplomat Dr. Monica Juma has officially assumed office as Director-General of the United Nations Office at Vienna and Executive Director of the United Nations Office on Drugs and Crime, with the rank of Under-Secretary-General. She expressed commitment to leading the UN's work in addressing drugs, organized crime, corruption, and terrorism.